Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating clinical depression: a randomized clinical trial
Sava F A, Yates B T, Lupu V, Szentagotai A, David D

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1002/jclp.20550

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Analysis of Variance; Antidepressive Agents, Second-Generation /administration & dosage /economics; Behavior Therapy /economics; Cognitive Therapy /economics; Cost-Benefit Analysis; Depressive Disorder, Major /diagnosis /economics /therapy; Female; Fluoxetine /administration & dosage /economics; Health Care Costs; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotherapy, Rational-Emotive /economics; Quality-Adjusted Life Years; Romania; Treatment Outcome; Young Adult

AccessionNumber
22009101122

Date bibliographic record published
20/05/2009